Alnylam Pharmaceuticals, Inc. Stock Analysis & AI Score
Alnylam Pharmaceuticals, Inc. (ALNY) has an ST Score of 60.6 (B), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $347.23 price target (+50.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIALNY Stock Price History
ALNY Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
ALNY Latest Stock News
ST Score
Alnylam Pharmaceuticals, Inc. (ALNY) has an ST Score of 60.6 (B), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $347.23 price target (+50.5% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- GrowthA+
- SentimentA+
- ForecastA-
- MomentumC
- Financial StrengthD
- ValuationF
- Piotroski6/9
Press Releases
Company Contact Details
ALNY stock: frequently asked questions
What is ALNY's ST Score?
Alnylam Pharmaceuticals, Inc. (ALNY) has an ST Score of 60.6 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ALNY a buy, hold, or sell?
Analysts rate ALNY a Buy, with a price target of $347.23 (+50.5% vs the current price). Our ST Score grades it B (60.6/100). The ST Score is a data-driven signal, not a recommendation.
What are ALNY's factor grades?
Valuation F, Profitability A+, Financial Strength D, Momentum C, Growth A+, Forecast A-, Sentiment A+.
What is ALNY's valuation grade?
Alnylam Pharmaceuticals, Inc. (ALNY) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ALNY's growth grade?
Alnylam Pharmaceuticals, Inc. (ALNY) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ALNY's profitability grade?
Alnylam Pharmaceuticals, Inc. (ALNY) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ALNY's financial strength grade?
Alnylam Pharmaceuticals, Inc. (ALNY) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ALNY?
The average analyst price target for Alnylam Pharmaceuticals, Inc. (ALNY) is $347.23 from 52 analysts, which is +50.5% versus the recent price of $230.71.
What is ALNY's Piotroski score?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.